How much funding has Prolium Bioscience raised?

Prolium Bioscience has raised $50.0M in total funding, most recently a Series A round.

Who are Prolium Bioscience's investors?

Prolium Bioscience's investors include RTW Investments.

When was Prolium Bioscience founded?

Prolium Bioscience was founded in 2025.

Where is Prolium Bioscience headquartered?

Prolium Bioscience is headquartered in New York, New York, United States.

What industry is Prolium Bioscience in?

Prolium Bioscience operates in Healthcare, Biotech.

How many employees does Prolium Bioscience have?

Prolium Bioscience has 1-10 employees.

Prolium Bioscience

Depleting Disease, Empowering Health

New York, United States · Founded 2025 · $50.0M raised

Healthcare

Biotech

Headquarters: New York, New York
Employees: 1–10
Founded: 2025
Business Model: B2B

Website: proliumbio.com
Total Funding: $50.0M
Last Round: $50.0M Series AMar 2026
Rounds: 1

About

Prolium Bioscience is a New York City-based clinical-stage biotechnology company developing PRO-203, a potential best-in-class bispecific CD20xCD3 T-cell engager for systemic sclerosis and other severe autoimmune diseases. Founded in 2025 and backed by RTW Investments with a $50M Series A, Prolium targets deep B-cell depletion for durable remissions in refractory autoimmune disease.

Summary

Prolium Bioscience is a Healthcare company based in New York, United States, founded in 2025. It has raised $50.0M in total across 1 round, most recently a $50.0M Series A round in Mar 2026. Investors include RTW Investments.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2026

$50.0M

Mar 2026

Investors

RTW Investments

Lead

1 round

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare

Growth Equity·$5.1B·Aug 2022

IVI-RMA

IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...

Valencia, Spain5001–10000Biotech, Healthcare

Private Equity·$3.3B·Apr 2022

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech

Series A·$3.0B·Jan 2022

inVentiv HealthAcquired

inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...

Burlington, United States5001–10000Biotech, Healthcare

Private Equity·$3.0B·May 2017

Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare

Private Equity·$3.0B·Jan 2004

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology

Corporate Round·$2.8B·Jan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

<a href="https://indexed.vc/companies/prolium-bioscience"><img src="https://indexed.vc/api/badge/company/prolium-bioscience" alt="Prolium Bioscience on Indexed.vc" width="260" height="76" /></a>